TL13-112 是一种有效的选择性 ALK-PROTAC 降解物，可抑制 ALK 活性，IC₅₀ 值 0.14 nM，并促进包括 Aurora A、FER、PTK2 和 RPS6KA1 在内的其他激酶的降解，IC₅₀ 值分别 8550 nM、42.4 nM、25.4 nM 和 677 nM。TL13-112 由 Ceritinib (HY-15656) 和 Cereblon 配体 Pomalidomide (HY-10984) 结合而成。

TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC 50 value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC 50 values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib (HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984).

Solid

Cereblon 2.4 μM (IC50)

TL13-112 binds to cereblon with an IC50 value of 2.4 uM.
TL13-112 (0.01 μM-1 μM; 16 hours) is selective for degradation of ALK with the DC50s of 10 nM and 40 nM in H3122 cell and Karpas 299, respectively. ALK degradation acts at 4 hours of treatment in H3122 cells and at 8 hours of treatment in Karpas 299 cells. The maximum degradation achieves at 16 hours in both cell lines. .
TL13-112 (0.01 μM-1 μM; 16 hours) inhibits PTK2, ALK, FER, RPS6KA1 and Aurora A expression as a dose-dependent manner in H3122, Karpas 299, and Kelly cells.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Powell CE, et al. Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).J Med Chem. 2018 May 10;61(9):4249-4255.

In Vitro: DMSO : 100 mg/mL (99.74 mM; ultrasonic and warming and heat to 60°C)配制储备液